The purpose of this prospective cohort study is to investigate whether antithrombotic therapy in the secondary prevention of ischemic stroke increases the risk of the emerging CMBs and whether the change is associated with an increased risk of intracranial hemorrhage, providing an imaging evidence for individualized antithrombotic therapy in such patients.
Patient age ≥18 years;
Acute ischemic stroke patient confirmed by imaging;
Time of onset: within 3 months;
Baseline SWI sequence is completed before starting the secondary prevention of ischemic stroke;
MRI contraindication;
Hemorrhagic transformation after acute Ischemic stroke;
Contraindication for antiplatelet or anticoagulation therapy;
Severe head trauma or intracranial hemorrhage occurred in the past six months;
ischemic stroke patients
Cohort
Prospective
SWI sequence
Other interventionAcute ischemic stroke patient confirmed by SWI sequence
all cerebral bleeding events
incidence of both cerebral microbleeds and intracranial hemorrhage, determined by MRI
all cerebral bleeding events
incidence of both cerebral microbleeds and intracranial hemorrhage, determined by MRI
proportion of mRS 0-1.
the minimum and maximum values of modified Rankin Score (mRS) are 0 and 6, respectively; higher score mean a worse outcome
proportion of cerebral microbleeds
cerebral microbleeds, determined by MRI
proportion of cerebral hemorrhage
cerebral hemorrhage, determined by MRI
Click on the lead sponsor to view all of their trials.
